Oxford Nanopore Technologies Plc, based in the United Kingdom, is a pharmaceutical company with a low-risk ESG score of 18.2. Specializing in cutting-edge DNA/RNA sequencing technology, the company offers fast, accessible, and user-friendly solutions for scientific and biomedical research. Their nanopore-based platform allows real-time analysis of genetic material, catering to fields like human genetics, cancer research, environmental analysis, and more. With a focus on Life Science Research Tools and COVID Testing, Oxford Nanopore Technologies PLC is a leader in ESG-friendly innovation in the pharmaceutical industry.